Navigation Links
Lazy eye treatment times could be drastically reduced, new research shows
Date:12/9/2008

Treatment times for amblyopia more commonly known as 'lazy eye' could be drastically reduced thanks to research carried out at The University of Nottingham.

Amblyopia is thought to affect up to 2.5 per cent of people and accounts for around 90 per cent of all children's eye appointments in the UK. Occlusion therapy patching the normal eye for lengthy periods to 'train' the affected eye is the main treatment for amblyopia. However, this method can be distressing to children, is unpopular with parents and can adversely effect educational development. This type of therapy has been used in various forms since 1743 and has long been considered to only be effective up until late childhood.

The new treatments developed in the Visual Neuroscience Group in the University's School of Psychology have not only reduced potential treatment times by an unprecedented amount, they have also proved that it is possible to treat amblyopia in adults. Early results suggest gains, that would have required around 120 hours of occlusion therapy to achieve, can be produced after just 10 hours.

Adult test subjects have undertaken challenging visual tasks under computer-controlled conditions. Academics hope that these promising results could be used to develop a child-friendly game that could treat amblyopia. There is also the potential to use these new treatments to supplement occlusion therapy.

The 60,000 project A Study of Perceptual Learning Effects in Amblyopia has been funded by the College of Optometrists. Amblyopia is a developmental problem in the brain, not the eye. The part of the brain dealing with vision from the affected eye develops abnormally as a result of atypical visual experience early in life. This results in markedly different levels of vision in each eye which cannot be remedied with spectacles.

As well as looking at potential treatments for the condition, the study examines the level of neural plasticity in the adult brain the ability of a neural system to change with experience.

The work is being carried out by Andrew Astle, a PhD student at the University.

"The results so far show a drastic improvement on patching, and disprove the long-held belief that adults cannot be treated for this type of condition," Andrew said. "However, the study is not complete and we're still looking for subjects to take part in the tests."

Work set to start in spring 2009 at the University will build on Andrew's results, examining amblyopia in children and examining the functional and structural organisation of the visual cortex. This EU-wide study has been funded by a European Consortium FP7 grant to the tune of 2.6m Euro. Professor Paul McGraw and Dr Ben Webb in the Visual Neuroscience Group will look at the effects and treatment of amblyopia in children. Other European institutions, including the University of Florence, the Max Planck Institute for Neuroscience and University College London, will examine the condition from the molecular level to its behavioural impact on animal models.

It is thought that results from this study could be translated to other conditions where recovery is limited due to restricted neural plasticity including brain tumours, stroke, degenerative diseases and trauma.

Professor McGraw said "Andrew's results suggest that the adult amblyopic visual system retains a great deal more neural plasticity than previously thought. Harnessing this plasticity offers a new way of treating this common condition and opens the door to developing novel pharmacological and behavioural interventions for a range of neurological deficits."


'/>"/>

Contact: Andrew Astle
lpxaa1@nottingham.ac.uk
44-011-595-15292
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Childrens cancer group recommends global evaluation system for neuroblastoma to improve treatment
2. UK kidney cancer patients face toxic, out-dated treatments with little hope of change
3. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
4. Juva Skin Center's Laser Skin Treatments Take an Innovative Leap with Pixel CO2 Device
5. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
6. Confusing risk information may lead breast cancer patients to make poor treatment choices
7. Precious metal could lead to next generation of cancer treatments
8. The St. John-Clark Pain Treatment Center Forms Manual Therapy 'Dream Team'
9. Novel treatments show improvements in survival and response rates for leukemia and lymphoma
10. Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma
11. Treatment Options Are Many for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Fla. (PRWEB) , ... April 29, 2016 , ... ... Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have better ... is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Mobility Designed ... put pressure on the armpits, the M+D Crutch evenly distributes body weight from the ... wrists and hands when using the crutches than with other crutches. , Co-founders Max ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... ... 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical Products, ... nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product ... a newly patented safety device secured by nasal surgeons onto the floor of the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed ... an upcoming episode, airing third quarter 2016 via Discovery Channel. Dates and show ... Grassland Dairy Products, located in Greenwood, Wisconsin applies product research and development and ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016   Acsis , ... announced that leading IT market research and advisory firm ... in the IDC MarketScape: Worldwide Pharmaceutical Track and Trace ... The report provides an assessment of the capabilities and ... and trace software market. Logo - ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
Breaking Medicine Technology: